Gapping down
In reaction to disappointing earnings/guidance:
- ONVO -17.2%, RSYS -15.3%, YELP -9.7%, UBNT -9.6%, CATM -7.3%, CERN -7%, MX -6.6%, SGEN -6.5%, IPAS -6.3%, MPWR -5.6%, CYBR -5.4%, MCFT -5%
- ZNGA -4.8%, ZAYO -3.2%, APTI -3.2%, SANW -3.2%, ALDW -2.6%, EGAN -2.4%, P -1.8%, TBBK -1.7%, CARB -1.4%, MHK -1.3%, AXL -0.9%, .
Select financial related names showing weakness:
- DB -2.2%, SAN -2.2%, RBS -2%, ING -1.7%, CS -1.6%, LYG -1.2%
Other news:
- MJN 5.2% (to be acquired by Reckitt Benckiser (RBGLY) for $90 per share)
- BSTG -37.6% (prices public offering with expected total gross proceeds of approx. $8.0 mln at $0.40/share)
- TCON -17.5% ( reports top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute )
- ICPT -11.3% (will provide an update on the Phase 3 REGENERATE trial of obeticholic acid in NASH patients with liver fibrosis during a conference call today)
- NDLS -9% (completes $18.5 mln private placement of Series A Convertible Preferred Stock and warrants to L Catterton, amends credit facility, and preannounces in-line Q4 revs; commences common stock offering; size not disclosed)
- BTX -8.6% (commences common stock offering)
- CLF -5.8% (upsizes offering by 5 mln shares and prices 55 mln shares of common stock at $10.75 per share)
- NBIX -0.8% (Neurocrine Biosci and BIAL enter into an exclusive licensing agreement for the development and commercialization of opicapone in North America)
Analyst comments:
- TWTR -1.9% (downgraded to Sell from Neutral at Citigroup)
- TEVA -1.1% (downgraded to Neutral from Buy at Mizuho)
- GBDC -0.9% (downgraded to Mkt Perform from Outperform at Raymond James)
- SBUX -0.6% (downgraded to Hold from Buy at Argus)